These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

750 related articles for article (PubMed ID: 23361084)

  • 61. A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.
    Burmester GR; McInnes IB; Kremer J; Miranda P; Korkosz M; Vencovsky J; Rubbert-Roth A; Mysler E; Sleeman MA; Godwood A; Sinibaldi D; Guo X; White WI; Wang B; Wu CY; Ryan PC; Close D; Weinblatt ME;
    Ann Rheum Dis; 2017 Jun; 76(6):1020-1030. PubMed ID: 28213566
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study.
    Kavanaugh A; McInnes IB; Mease PJ; Krueger GG; Gladman DD; van der Heijde D; Mudivarthy S; Xu W; Mack M; Xu Z; Beutler A
    Ann Rheum Dis; 2013 Nov; 72(11):1777-85. PubMed ID: 23161902
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Minimal Disease Activity Among Active Psoriatic Arthritis Patients Treated With Secukinumab: 2-Year Results From a Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study.
    Coates LC; Mease PJ; Gossec L; Kirkham B; Sherif B; Gaillez C; Mpofu S; Jugl SM; Karyekar C; Gandhi KK
    Arthritis Care Res (Hoboken); 2018 Oct; 70(10):1529-1535. PubMed ID: 29409133
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis.
    Mease PJ; Genovese MC; Greenwald MW; Ritchlin CT; Beaulieu AD; Deodhar A; Newmark R; Feng J; Erondu N; Nirula A
    N Engl J Med; 2014 Jun; 370(24):2295-306. PubMed ID: 24918373
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
    Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study.
    McInnes IB; Mease PJ; Schett G; Kirkham B; Strand V; Williams N; Fox T; Pricop L; Jugl SM; Gandhi KK;
    Arthritis Res Ther; 2018 Jun; 20(1):113. PubMed ID: 29880010
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial.
    Brunner HI; Foeldvari I; Alexeeva E; Ayaz NA; Calvo Penades I; Kasapcopur O; Chasnyk VG; Hufnagel M; Żuber Z; Schulert G; Ozen S; Rakhimyanova A; Ramanan A; Scott C; Sozeri B; Zholobova E; Martin R; Zhu X; Whelan S; Pricop L; Martini A; Lovell D; Ruperto N;
    Ann Rheum Dis; 2023 Jan; 82(1):154-160. PubMed ID: 35961761
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Treatment of psoriatic arthritis with secukinumab: a case series.
    Nicola S; Rolla G; Monti R; Brussino L
    J Dermatolog Treat; 2018; 29(sup1):6-8. PubMed ID: 30247936
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Phase II Study of ABT-122, a Tumor Necrosis Factor- and Interleukin-17A-Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate.
    Mease PJ; Genovese MC; Weinblatt ME; Peloso PM; Chen K; Othman AA; Li Y; Mansikka HT; Khatri A; Wishart N; Liu J
    Arthritis Rheumatol; 2018 Nov; 70(11):1778-1789. PubMed ID: 29855175
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Relative efficacy and safety of secukinumab and guselkumab for the treatment of active psoriatic arthritis: A network meta-analysis.
    Song GG; Lee YH
    Int J Clin Pharmacol Ther; 2021 Jun; 59(6):433-441. PubMed ID: 33860750
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1).
    van der Heijde D; Gladman DD; Kishimoto M; Okada M; Rathmann SS; Moriarty SR; Shuler CL; Carlier H; Benichou O; Mease PJ
    J Rheumatol; 2018 Mar; 45(3):367-377. PubMed ID: 29247148
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial.
    Bingham CO; Mendelsohn AM; Kim L; Xu Z; Leu J; Han C; Lo KH; Westhovens R; Weinblatt ME;
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1627-36. PubMed ID: 25623393
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1).
    Strand V; Mease P; Gossec L; Elkayam O; van den Bosch F; Zuazo J; Pricop L; Mpofu S;
    Ann Rheum Dis; 2017 Jan; 76(1):203-207. PubMed ID: 27169431
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial.
    Huizinga TW; Fleischmann RM; Jasson M; Radin AR; van Adelsberg J; Fiore S; Huang X; Yancopoulos GD; Stahl N; Genovese MC
    Ann Rheum Dis; 2014 Sep; 73(9):1626-34. PubMed ID: 24297381
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.
    McInnes IB; Kavanaugh A; Gottlieb AB; Puig L; Rahman P; Ritchlin C; Brodmerkel C; Li S; Wang Y; Mendelsohn AM; Doyle MK;
    Lancet; 2013 Aug; 382(9894):780-9. PubMed ID: 23769296
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study).
    Kavanaugh A; McInnes IB; Mease P; Krueger GG; Gladman D; van der Heijde D; Zhou Y; Lu J; Leu JH; Goldstein N; Beutler A
    Ann Rheum Dis; 2014 Sep; 73(9):1689-94. PubMed ID: 24748630
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study.
    Østergaard M; Baslund B; Rigby W; Rojkovich B; Jorgensen C; Dawes PT; Wiell C; Wallace DJ; Tamer SC; Kastberg H; Petersen J; Sierakowski S
    Arthritis Rheum; 2010 Aug; 62(8):2227-38. PubMed ID: 20506254
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial.
    Ritchlin CT; Coates LC; Mease PJ; van der Heijde D; Song J; Jiang Y; Shawi M; Kollmeier AP; Rahman P
    Trials; 2023 Jan; 24(1):22. PubMed ID: 36627711
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.
    Deodhar A; Mease PJ; McInnes IB; Baraliakos X; Reich K; Blauvelt A; Leonardi C; Porter B; Das Gupta A; Widmer A; Pricop L; Fox T
    Arthritis Res Ther; 2019 May; 21(1):111. PubMed ID: 31046809
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study).
    Kennedy WP; Simon JA; Offutt C; Horn P; Herman A; Townsend MJ; Tang MT; Grogan JL; Hsieh F; Davis JC
    Arthritis Res Ther; 2014 Oct; 16(5):467. PubMed ID: 25359150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.